aTyr Pharma is a clinical-stage biotechnology company that develops therapies targeting fibrosis and inflammation using a proprietary platform based on extracellular tRNA synthetase biology. The company's lead program, efzofitimod, is a biologic immunomodulator in development for interstitial lung disease, a group of immune-mediated lung disorders, with particular focus on pulmonary sarcoidosis and systemic sclerosis-associated ILD; the company also has earlier-stage candidates targeting fibrotic diseases across multiple organs. aTyr aims to generate revenue through regulatory approval and commercialization of its drug candidates, supplemented by partnership agreements such as its Japan-based collaboration with Kyorin, while building selective commercial infrastructure and outsourcing manufacturing to contract organizations.